



NZX/ASX Announcement

29 May 2026

TruScreen FY2026 Preliminary Results

(all numbers in NZ dollars)

Cervical cancer technology company Truscreen Group Limited (NZX/ASX: TRU) (the Company) has today released its preliminary unaudited financial results for the financial year ended 31 March 2026.

Highlights include:

- Launch of 5-year programme to screen 260,000 women for cervical cancer in Ho Chi Minh City, Vietnam
- TruScreen re-enters the Indian market and appoints Renovate Biologicals Pvt Ltd to distribute its AI enabled TruScreen cervical cancer screening system in India
- Landmark publication of the multi year and multi province clinical trial by Germany's BMC Cancer. Notable publications including Sichuan University clinical study, and the Guilin People's Hospital study, confirm TruScreen's superiority as a primary screening medical device, and a superior screening choice for pregnant women
- TruScreen submitted three proposals to UNITAID's Global Cervical Cancer Elimination Call to Action, covering 14 high burden countries and an addressable screening market of 1Bn women.
- Growing TruScreen's distribution network with appointment of new distributors in South Africa and Uzbekistan, with pending appointments in Nigeria, Romania, Bangladesh and Sri Lanka

Financial year 31 March 2026 was a year of marketing growth and consolidation for TruScreen.

Truscreen achieved product sales growth of 42% YOY to FY2026, and the sales were achieved from a broader range of participant countries. This included first sales in India with 468 million¹ screening-age women and Indonesia with 95 million² of screening age and a government funded mass screening program, creating enormous growth opportunity.

TruScreen is accelerating new market development, with a diversified geographic distribution footprint that will provide leverage to improve commercial returns. TruScreen's additional drive to participate in public screening programmes requires investment, but achieving scale and meeting clinical need will shorten the pathway to profitability.

TruScreen has recently submitted three proposals to UNITAID for cervical cancer screening programmes across 14 high-burden countries in Africa, Asia-Pacific, and Latin America – addressable market 1Bn women, with potential revenue as a consortium lead for TruScreen of up to US\$18.4 million. TruScreen's point-of-care portable AI technology is purpose-built for the settings where cervical cancer kills most, where there are no laboratories, no pathologists, and no patient recall second visit.

¹ *CIA World Factbook women aged 15-64 = 467,593,7814


²*CIA World Factbook women aged 15-64 = 95,961,293



TruScreen enables primary screening where labs are absent, HPV triage where HPV (including Dalton Bio) is primary, and same-visit complement in screen-and-treat settings. This creates a complementary rather than competitive relationship with HPV expansion.

Gross margin in FY2026 was 31.5% (2025: 30.1%). Gross margin is expected to further improve in FY2027 with revenue from a broader range of countries. Other income was in line with the prior year at \$0.4m (2025: \$0.4m).

Total overhead expenses were \$3.4m (2025: \$3.1m) reflecting additional marketing and support costs as the Company strives to broaden its revenue base. The result for the year was a loss of \$2.25m (2025: \$2.24m) with the additional margin on revenue being offset by additional costs incurred as the Company grew its distributor base and focus on large public screening programmes in collaboration with global NGO's working with countries to meet WHO's **90-70-90** milestones by 2030.



TruScreen in FY2026 expanded its reach into a number of new countries. A brief summary of development by country is as follows:

China

- China remained our largest market, accounting for 61.3% of total sales. Despite challenging economic conditions, consumable sales volume met expectations.
- Landmark clinical study results from the Chinese Obstetricians and Gynaecologists Association (COGA) were published in the leading German journal BMC Cancer and Springer Nature Link in February 2026. This largest-ever study of opto-electronic cervical screening further validated TruScreen as a superior primary cervical cancer screening tool.



Vietnam

- TruScreen was successfully adopted by four leading public hospitals in South Vietnam, establishing a foundation for broader hospital acceptance.
- TruScreen has entered the growing private health sector. One hospital has integrated TruScreen into its daily clinic operations, while four additional clinics are awaiting government approval for installation and three more are preparing their application documentation for submission.

Indonesia

- The pilot clinical study is currently underway. Results will be presented by the lead investigator at the Annual Scientific Meeting of POGI (the Indonesian Obstetrics and Gynaecology Association) in July 2026. TruScreen and distributor Marwa Mitra Medika are sponsoring the conference and will conduct a symposium to launch TruScreen in Indonesia.
- Leveraging the pilot clinical study results, Marwa Mitra Medika will collaborate with the Ministry of Health to include TruScreen in government public screening programs.

India

- New distributor Renovate Biological was appointed in April 2025.
- Interim Product Testing license was obtained in July 2025, permitting Renovate Biological to import up to 10 TruScreen devices, which have been shipped, for clinical study and training purposes. A consortium of private hospitals will adopt TruScreen subject to regulatory approval.
- Application for regulatory approval was submitted in April 2026, with approval expected within 3 to 6 months.

Singapore, Malaysia and Thailand

- Product registration with Singapore's HSA was obtained in September 2025.
- Product registration with Thailand's FDA was obtained in April 2026.
- Product registration in Malaysia was submitted in March 2026, with approval expected shortly.
- A reference centre for S E Asia has been established in Singapore with local Key Opinion Leader, Dr. S. C. Quek at the Parkway Gynaecology Screening & Treatment Centre, Gleneagles Hospital.

Bangladesh

- New distributor Xerox Medica Limited was appointed in May 2026, with potential first-year sales in FY2027.
- Government procurement application to be submitted in June 2026 to meet government budget deadline.

Mexico

- Distributor Sunbird launched social media and digital marketing campaigns, established online training and information centres for TruScreen. It generated significant interest, and is building a strong sales pipeline.
- TruScreen has entered the laboratory system where large volumes of cervical cancer screenings are conducted. Sunbird is in discussions to collaborate with major laboratory chains. Sales are expected to commence in FY2027.

Uzbekistan

- New distributor appointed in May 2026. Albatros Health Care LLC is a leading medical device distributor in the country. The potential sales revenue for the 30-month period through calendar year 2028 is over NZD 1 million.



- Led by a senior government medical advisor, and with ethics approval, the pilot Clinical study will commence in June 2026.

Central Asia

- Distributor IMSystem is conducting a multi-centre clinical study to meet requirements for TruScreen to be recognized as a primary screening method in all government healthcare providers and screening programs. Two centres have begun screening 1,500 women, with two additional centres commencing in May 2026 to screen the remaining 500 women.
- Kazakhstan will commence commercial use of TruScreen in early FY2027. Product registrations have been submitted in Kyrgyzstan and Belarus, with approvals expected in Q3 FY2027.

Zimbabwe

- The re-validation study was completed by the National Microbiology Reference Laboratory in August 2025. The positive results enabled the Ministry of Health to approve TruScreen as a primary screening test for locations where HPV DNA testing is unavailable and as a confirmatory test for HPV-positive women nationwide. This is an expansion from the previous single-province deployment.
- Following re-validation, the screening program resumed with a planned 20,000 screenings in calendar year 2026.

South Africa

- New distributor AIR was appointed in November 2025.
- Product registration with the South African Health Products Regulatory Authority (SAHPRA) was submitted in March 2026, with approval expected in July 2026.
- A pilot clinical study to support market entry has been planned to commence when regulatory approval is received.

Nigeria

- TruScreen collaborated with Nigeria's Lagos State University Teaching Hospital (LASUTH) and Lagos State University College of Medicine (LASUCOM) on a Bill & Melinda Gates Foundation grant application. Dr. Ayokunle Moses Olumodeji, Consultant Gynaecological Oncologist at LASUTH, selected TruScreen's AI-enabled cervical cancer screening medical device as the cornerstone of his proposed study to validate TruScreen's integration into existing clinical settings.
- The first clinical reference centre in Africa will be established in Nigeria with Professor Chibuiké Chigbu at University of Nigeria Teaching Hospital.
- Collaborative relationships have been developed with local NGOs including Solina Centre for International Development and Research (SCIDaR) and RedAid.

Other new distributors appointed include Romania and Italy. We are in final discussions with potential distributors in Nigeria, Rwanda, Sri Lanka, and Palestine.



Corporate

The Company raised approximately \$4 million during the year, with the issue of approximately 190.7 million shares at \$0.022 per share. These funds have enabled the Company to expand its geographic reach and engage in new initiatives which have strengthened the foundation for improved financial performance in FY2027.

Attached to these shares is one free attaching option, exercisable at \$0.022, which term has been extended to 17 July 2027.

Ms Juliet Hull retired as a director at the annual shareholders meeting on 11 September and Ms Christine Pears was elected by shareholders as a director. She has over 20 years' experience as Chair, independent director and executive of both listed and private companies.

Our CEO, Martin Dillon, as foreshadowed in an announcement in February 2026, will rejoin the Company on 1 June 2026 and will be key in TruScreen's drive for transformational growth.

Mr Chris Horn, as advised in early April 2026 will retire shortly after thirteen years as a director of the Company. The Company is currently seeking to appoint an Australian based Non-executive director.

Authorised by the Board for filing with the NZX/ASX.

For more information, visit www.truscreen.com or contact:

Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Jack Zhang
Media & Investor Relations
jack@sparkplus.org



About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra[®], is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2025 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*

About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening. DALTONbio's exceptional, clinically proven products have saved tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day.



To learn more, please visit: www.daltonbio.com/.



a world without cervical cancer

TruScreen Group Ltd | NZBN 9429030105614

TRU.NZ | TRU.AX | info@truscreen.com

Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia



NATIONAL MEDICAL PRODUCTS ADMINISTRATION
国家药品监督管理局